ArticleAMB Express2025
Characterization of a newly isolated biosurfactant fengycin produced by Heyndrickxia coagulans strain.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
One of the major global concerns in human and veterinary medicine at present is the antimicrobial resistance to conventional antibiotics. Natural products from microbial sources appear to be the most favorable alternative to current antibiotics. Biosurfactants (BSs) are surface-active compounds synthesised by a wide variety of microorganisms. Fengycin is an important member of the lipopeptide family, with a wide range of applications in different industries and a broad spectrum of antimicrobial activity against pathogenic microbes. The production of fengycin has been detected in various strains of Bacillus spp., but to our knowledge, not in Heyndrickxia coagulans. Strain H. coagulans (formerly known as B. coagulans) Biocenol™ 9FT27 CCM 9014, which exhibited surfactant activity as assessed by oil spreading assay, was characterised using the 16S rRNA sequencing method. PCR screening detected the presence of fenD, indicating the production of the lipopeptide biosurfactant fengycin. The results of UHPLC-DAD, NMR and MALDI-TOF/MS analysis confirmed the production of fengycin by H. coagulans 9FT27. BS was found to significantly (P < 0.0001) inhibit the biofilm formation of Staphylococcus aureus CCM 4223 and MRSA (methicillin-resistant Staphylococcus aureus) at concentrations ranging from 15 to 0.2 mg/mL. Analysis of qRT-PCR results revealed reduced expression of the srtA, gyrB, clfB and icaADB operon genes, which are associated with biofilm formation. Our results indicate the potential of fengycin in the control of biofilm-related infections, especially those caused by antibiotic-resistant S. aureus strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.